A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Bristol-Myers Squibb
Taiho Oncology, Inc.
Astellas Pharma Inc
Astellas Pharma Inc
Arcus Biosciences, Inc.
Arcus Biosciences, Inc.
Arcus Biosciences, Inc.
Pfizer
Akeso
Seagen Inc.
Astellas Pharma Inc
OncoSil Medical Limited
FBD Biologics Limited
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
AbbVie
Revolution Medicines, Inc.
Enliven Therapeutics
Akeso
Bristol-Myers Squibb
ITM Solucin GmbH
Pfizer
Toray Industries, Inc
Lisata Therapeutics, Inc.
Seattle Project Corporation
Merck Sharp & Dohme LLC
Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd.